| All 3 treatment groups (n = 72) F45, M27 Follow up length median 25 weeks | Alirocumab 75 mg (n = 25) F12, M13 Follow up length median 24 weeks | Alirocumab 150 mg (n = 15) F10, M5 Follow up length median 26 weeks | Evolocumab 140 mg (n = 32) F23, M9 Follow up length median 24 weeks |
---|---|---|---|---|
Flu-like myositis | 8 (10%) | 1 (4%) | 5 (33%) | 2 (6%) |
Respiratory tract infection/symptoms | 6 (8%) | 1 (4%) | 1 (7%) | 4 (13%) |
Inject site reaction | 4 (6%) | 1 (4%) | 1 (7%) | 2 (6%) |
Fatigue | 1 (1%) | 1 (4%) | Â | Â |
Headache/mental acuity/mood | 2 (3%) | Â | 1 (7%) | 1 (3%) |
Urticaria/itchiness | 2 (3%) | 1 (4%) | Â | 1 (3%) |
G.I. symptom | 2 (3%) | Â | 1 (7%) | 1 (3%) |
Weight gain | 1 (1%) | Â | Â | 1 (3%) |
Hair loss | 1 (1%) | Â | Â | 1 (3%) |
Any adverse events | 22 (31%) | 5 (20%) | 7 (47%) | 10 (31%) |
No adverse events | 50 (69%) | 20 (80%) | 8 (53%) | 22 (69%) |